From Wikipedia, the free encyclopedia

Jump to: navigation, search
Remoxipride Structural Formulae.png
Systematic (IUPAC) name
Clinical data
Trade names Roxiam
Legal status
  • Withdrawn
Routes of
Pharmacokinetic data
Bioavailability 96%[1]
Protein binding 89-98%
Metabolism Hepatic[1]
Biological half-life 4-7 hours[1]
Excretion Renal[1]
CAS Registry Number 117591-79-4 N
ATC code N05AL04
PubChem CID: 54477
DrugBank DB00409 YesY
ChemSpider 49195 YesY
UNII 0223RD59PE YesY
KEGG D02683 YesY
Chemical data
Formula C16H23BrN2O3
Molecular mass 371.27 g/mol
 N (what is this?)  (verify)

Remoxipride (Roxiam) is an atypical antipsychotic (although according to some sources it is a typical antipsychotic) which was previously used in Europe for the treatment of schizophrenia and acute mania but was withdrawn due to toxicity concerns (incidence of aplastic anemia in 1/10,000 patients).[2] It was initially launched by AstraZeneca in 1990 and suspension of its use began in 1993.[2] Remoxipride acts as a selective D2 and D3 receptor antagonist and also has high affinity for the sigma receptor, possibly playing a role in its atypical neuroleptic action.[3]

Due to its short half-life twice daily (bid) dosing is required, although a once-daily controlled-release tablet has been developed.[4] There was some interest in its use in the treatment of treatment-resistant schizophrenia.[5][6]


Specific dopamine D2-receptor antagonist.

Remoxipride synthesis:[7] eidem,[8]

Bromination of acid 1' followed by reaction of the product (2), as its acid chloride, with the (S)-(–)-aminomethylpyrrolidine, gives remoxipride with (S)-configuration.

See also[edit]


  1. ^ a b c d Grind, M; Nilsson, MI; Nilsson, L; Oxenstierna, G; Sedvall, G; Wahlén, A (1989). "Remoxipride - a new potential antipsychotic compound: tolerability and pharmacokinetics after single oral and intravenous administration in healthy male volunteers". Psychopharmacology 98 (3): 304-309. doi:10.1007/bf00451679. PMID 2568653. 
  2. ^ a b José Miguel Vela; Helmut Buschmann; Jörg Holenz; Antonio Párraga; Antoni Torrens (2007). Antidepressants, Antipsychotics, Anxiolytics: From Chemistry and Pharmacology to Clinical Application. Weinheim: Wiley-VCH. ISBN 3-527-31058-4. 
  3. ^ Köhler C, Hall H, Magnusson O, Lewander T, Gustafsson K (1990). "Biochemical pharmacology of the atypical neuroleptic remoxipride". Acta Psychiatrica Scandinavica. Supplementum 358: 27–36. PMID 1978484. 
  4. ^ Alexander, MS; Chakravarti, SK; Sundararajan, K; Mullin, JM; Shaw, SH; Blomqvist, M; Lockett, CM (January 1993). "Once-daily controlled release remoxipride is equieffective with twice-daily immediate release remoxipride in the treatment of schizophrenia". Journal of Psychopharmacology 7 (3): 276-82. doi:10.1177/026988119300700307. PMID 22290842. 
  5. ^ Conley, R; Dixon, L; An Nguyen, R; Taminga, C; Hain, R (April 1993). "Remoxipride therapy in treatment resistant schizophrenia". Schizophrenia Research 9 (2-3): 235-236. doi:10.1016/0920-9964(93)90521-J. 
  6. ^ Conley, R; Dixon, L; An Nguyen, R; Taminga, C; Raymond, R (April 1993). "Remoxipride therapy in poorly responsive schizophrenics". Schizophrenia Research 4 (3): 316. doi:10.1016/0920-9964(91)90208-9. 
  7. ^ G. L. Florvall, S. O. Ogren, EP 4831 ; eidem, U.S. Patent 4,232,037 (1979, 1980 both to Astra).
  8. ^ doi:10.1021/jm00353a003
    This citation will be automatically completed in the next few minutes. You can jump the queue or expand by hand

External links[edit]